AMDL Reports 2004 First Quarter Financial Results
May 14 2004 - 5:00AM
PR Newswire (US)
AMDL Reports 2004 First Quarter Financial Results TUSTIN, Calif.,
May 14 /PRNewswire-FirstCall/ -- AMDL, Inc. , developer and
marketer of tests for the early detection of cancer and other
serious diseases, reported results for the three months ended March
31, 2004. AMDL's product revenues for the three months ended March
31, 2004 totaled $124,503, an 88.5 percent increase compared to
product revenues of $66,036 for the three months ended March 31,
2003. Net loss for the three months ended March 31, 2004 was
$564,256 or ($0.03) per share compared to a net loss of $571,033,
or ($0.06) per share, for the three months ended March 31, 2003.
"The Company's primary objective remains receiving U.S. Food and
Drug Administration clearance to market its DR-70(R) test in the
U.S. FDA approval would simultaneously increase market awareness
and acceptance in international markets," Gary L. Dreher, CEO of
AMDL, said. "The Company is also seeking to license its Combination
Immune Therapy technology through a strategic relationship with a
large pharmaceutical company." About AMDL AMDL, Inc. (AMEX:ADL),
headquartered in Tustin, California, is a theranostics company,
involved in the detection and treatment of the same disease,
cancer. AMDL is the inventor, developer and worldwide marketer
through exclusive distribution agreements of the DR-70(R)
non-invasive cancer blood test, which has demonstrated its ability
to detect the presence in humans of up to 13 cancers 84 percent of
the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdlcorporate.com/. Forward-Looking Statements
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's partners that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdlcorporate.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024